Compare CRSP & FND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | FND |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.3B |
| IPO Year | 2016 | 2014 |
| Metric | CRSP | FND |
|---|---|---|
| Price | $52.09 | $47.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 16 |
| Target Price | $70.29 | ★ $73.44 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.05 |
| EPS | N/A | ★ 1.25 |
| Revenue | $289,590,000.00 | ★ $4,684,088,000.00 |
| Revenue This Year | $807.72 | $7.53 |
| Revenue Next Year | $172.52 | $7.68 |
| P/E Ratio | ★ N/A | $38.06 |
| Revenue Growth | ★ 9169.85 | 5.12 |
| 52 Week Low | $44.12 | $42.64 |
| 52 Week High | $78.48 | $92.41 |
| Indicator | CRSP | FND |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 31.92 |
| Support Level | $50.45 | $46.29 |
| Resistance Level | $60.41 | $53.19 |
| Average True Range (ATR) | 2.27 | 1.75 |
| MACD | -0.79 | -0.65 |
| Stochastic Oscillator | 4.25 | 7.54 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.